Moderna, Inc. (MRNA)
NASDAQ: MRNA · Real-Time Price · USD
145.55
-3.32 (-2.23%)
At close: Sep 4, 2026, 4:00 PM EDT
145.00
-0.55 (-0.38%)
After-hours: Sep 4, 2026, 7:59 PM EDT
Moderna Revenue
Moderna had revenue of $145.00M in the quarter ending June 30, 2026, with 2.11% growth. This brings the company's revenue in the last twelve months to $2.23B, down -56.76% year-over-year. In the year 2025, Moderna had annual revenue of $1.94B, down -39.93%.
Revenue (ttm)
$2.23B
Revenue Growth
-56.76%
P/S Ratio
26.08
Revenue / Employee
$474,043
Employees
4,700
Market Cap
58.11B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.94B | -1.29B | -39.93% |
| Dec 31, 2024 | 3.24B | -3.61B | -52.75% |
| Dec 31, 2023 | 6.85B | -12.42B | -64.45% |
| Dec 31, 2022 | 19.26B | 792.00M | 4.29% |
| Dec 31, 2021 | 18.47B | 17.67B | 2,200.25% |
| Dec 31, 2020 | 803.00M | 743.00M | 1,238.33% |
| Dec 31, 2019 | 60.00M | -75.07M | -55.58% |
| Dec 31, 2018 | 135.07M | -70.76M | -34.38% |
| Dec 31, 2017 | 205.83M | 97.43M | 89.88% |
| Dec 31, 2016 | 108.40M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Regeneron Pharmaceuticals | 15.53B |
| Vertex Pharmaceuticals | 12.59B |
| BeOne Medicines AG | 6.13B |
| Incyte | 5.82B |
| argenx SE | 5.32B |
| Alnylam Pharmaceuticals | 4.80B |
| BioNTech SE | 3.03B |
| Royalty Pharma | 2.54B |
MRNA News
- 1 day ago - Moderna (MRNA) Price Forecast: Bullish Pennant Points Toward Higher Targets - FXEmpire
- 1 day ago - Healthcare Stocks Pick Up Steam as Investors Play Offense and Defense - Barrons
- 1 day ago - Why Moderna Stock's Cancer Vaccine Rally Sparked a Rare Sell Rating - Barrons
- 2 days ago - Moderna Stock (MRNA) Drops as Rothschild Downgrades to ‘Sell’ on Valuation Concerns - TipRanks
- 2 days ago - Moderna downgraded to Sell from Neutral at Rothschild & Co Redburn - TheFly
- 2 days ago - Why Moderna's Cancer Vaccine Matters to Investors - ETF Trends
- 4 days ago - Moderna to Present at Upcoming Conferences in September 2026 - Accesswire
- 4 days ago - Moderna Stock (MRNA) Was the Best Performer in August - TipRanks